共 88 条
[1]
Drummond MF(2007)Assessing the economic challenges posed by orphan drugs Int J Technol Assess Health Care 23 36-42
[2]
Picavet E(2015)What is known about the cost-effectiveness of orphan drugs? Evidence form cost-utility analyses J Clin Pharm Ther 40 304-7
[3]
Cassiman D(2011)Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions Int J Technol Assess Health Care 27 71-6
[4]
Simoens S(2007)NICE’s cost effectiveness threshold BMJ 335 358-9
[5]
Cleemput I(2014)Are payers treating orphan drugs differently? J Market Access Health Policy 2 23513-39
[6]
Neyt M(2012)Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 7 74-95
[7]
Thiry N(1991)Integrating multi-criteria evaluation with geographical information systems Int J Geogr Inf Syst 5 321-13
[8]
De Laet C(2003)The relevance of MCDM for financial decisions J Multi-Criteria Decis Anal 11 187-32
[9]
Leys M(2012)Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand Health Res Policy Syst 10 6-46
[10]
Appleby J(2013)Balancing efficiency, equity and feasbility of HIV treatment in South Africa – development of programmatic guidance Cost Eff Resour Alloc 11 26-26